O	O	O	0	10	Peripheral	Peripheral	B-NP	JJ	B-cell_type	4	NMOD	B-cell_type
O	O	O	11	16	blood	blood	I-NP	NN	I-cell_type	4	NMOD	I-cell_type
O	O	O	17	28	mononuclear	mononuclear	I-NP	JJ	I-cell_type	4	NMOD	I-cell_type
O	O	O	29	34	cells	cell	I-NP	NNS	I-cell_type	11	SUB	I-cell_type
O	O	O	35	43	isolated	isolate	B-VP	VBN	O	4	NMOD	O
O	O	O	44	48	from	from	B-PP	IN	O	5	VMOD	O
O	O	O	49	57	patients	patient	B-NP	NNS	O	6	PMOD	O
O	O	O	58	62	with	with	B-PP	IN	O	7	NMOD	O
O	O	O	63	71	diabetic	diabetic	B-NP	JJ	O	10	NMOD	O
O	O	O	72	83	nephropathy	nephropathy	I-NP	NN	O	8	PMOD	O
O	O	O	84	88	show	show	B-VP	VBP	O	0	ROOT	O
O	O	O	89	98	increased	increase	B-NP	VBN	O	13	NMOD	O
O	O	O	99	109	activation	activation	I-NP	NN	O	11	OBJ	O
O	O	O	110	112	of	of	B-PP	IN	O	13	NMOD	O
O	O	O	113	116	the	the	B-NP	DT	O	24	NMOD	O
O	O	O	117	126	oxidative	oxidative	I-NP	JJ	O	24	NMOD	O
O	O	O	126	127	-	-	I-NP	HYPH	O	24	NMOD	O
O	O	O	127	133	stress	stress	I-NP	NN	O	24	NMOD	O
O	O	O	134	143	sensitive	sensitive	I-NP	JJ	O	18	AMOD	O
O	O	O	144	157	transcription	transcription	I-NP	NN	O	24	NMOD	O
O	O	O	158	164	factor	factor	I-NP	NN	O	24	NMOD	O
T3	B-Entity	B-Entity	165	167	NF	NF	I-NP	NN	B-protein	24	NMOD	B-protein
T3	I-Entity	I-Entity	167	168	-	-	B-NP	HYPH	I-protein	24	NMOD	I-protein
T3	I-Entity	I-Entity	168	174	kappaB	kappaB	I-NP	NN	I-protein	14	PMOD	I-protein
O	O	O	174	175	.	.	O	.	O	11	P	O

O	O	O	177	186	Increased	Increase	B-NP	VBN	O	3	NMOD	O
O	O	O	187	196	oxidative	oxidative	I-NP	JJ	O	3	NMOD	O
O	O	O	197	203	stress	stress	I-NP	NN	O	6	NMOD	O
O	O	O	204	207	and	and	O	CC	O	6	NMOD	O
O	O	O	208	218	subsequent	subsequent	B-NP	JJ	O	6	NMOD	O
O	O	O	219	229	activation	activation	I-NP	NN	O	14	SUB	O
O	O	O	230	232	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	233	236	the	the	B-NP	DT	O	10	NMOD	O
T4	B-Entity	B-Entity	237	250	transcription	transcription	I-NP	NN	B-protein	10	NMOD	B-protein
T4	I-Entity	I-Entity	251	257	factor	factor	I-NP	NN	I-protein	13	NMOD	I-protein
T4	I-Entity	I-Entity	258	260	NF	NF	I-NP	NN	B-protein	13	NMOD	B-protein
T4	I-Entity	I-Entity	260	261	-	-	B-NP	HYPH	I-protein	13	NMOD	I-protein
T4	I-Entity	I-Entity	261	267	kappaB	kappaB	I-NP	NN	I-protein	7	PMOD	I-protein
O	O	O	268	271	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	272	276	been	be	I-VP	VBN	O	14	VC	O
O	O	O	277	283	linked	link	I-VP	VBN	O	15	VC	O
O	O	O	284	286	to	to	B-PP	TO	O	16	VMOD	O
O	O	O	287	290	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	291	302	development	development	I-NP	NN	O	17	PMOD	O
O	O	O	303	305	of	of	B-PP	IN	O	19	NMOD	O
O	O	O	306	310	late	late	B-NP	JJ	O	23	NMOD	O
O	O	O	311	319	diabetic	diabetic	I-NP	JJ	O	23	NMOD	O
O	O	O	320	333	complications	complication	I-NP	NNS	O	20	PMOD	O
O	O	O	333	334	.	.	O	.	O	14	P	O

O	O	O	335	337	To	To	B-VP	TO	O	2	VMOD	O
O	O	O	338	347	determine	determine	I-VP	VB	O	19	VMOD	O
O	O	O	348	355	whether	whether	B-SBAR	IN	O	2	VMOD	O
O	O	O	356	365	oxidative	oxidative	B-NP	JJ	O	5	AMOD	O
O	O	O	366	372	stress	stress	I-NP	NN	O	10	NMOD	O
O	O	O	373	382	dependent	dependent	I-NP	JJ	O	5	AMOD	O
T5	B-Entity	B-Entity	383	385	NF	NF	I-NP	NN	B-protein	10	NMOD	B-protein
T5	I-Entity	I-Entity	385	386	-	-	O	HYPH	I-protein	10	NMOD	I-protein
T5	I-Entity	I-Entity	386	392	kappaB	kappaB	B-NP	NN	I-protein	10	NMOD	I-protein
O	O	O	393	403	activation	activation	I-NP	NN	O	11	SUB	O
O	O	O	404	406	is	be	B-VP	VBZ	O	3	SBAR	O
O	O	O	407	414	evident	evident	B-ADJP	JJ	O	11	PRD	O
O	O	O	415	417	in	in	B-PP	IN	O	11	VMOD	O
O	O	O	418	426	patients	patient	B-NP	NNS	O	13	PMOD	O
O	O	O	427	431	with	with	B-PP	IN	O	14	NMOD	O
O	O	O	432	440	diabetic	diabetic	B-NP	JJ	O	17	NMOD	O
O	O	O	441	452	nephropathy	nephropathy	I-NP	NN	O	15	PMOD	O
O	O	O	453	455	we	we	B-NP	PRP	O	19	SUB	O
O	O	O	456	460	used	use	B-VP	VBD	O	0	ROOT	O
O	O	O	461	463	an	an	B-NP	DT	O	28	NMOD	O
O	O	O	464	479	Electrophoretic	Electrophoretic	I-NP	JJ	O	24	AMOD	O
O	O	O	480	488	Mobility	Mobility	I-NP	NN	O	24	AMOD	O
O	O	O	489	494	Shift	Shift	I-NP	NN	O	24	AMOD	O
O	O	O	495	500	Assay	Assay	I-NP	NN	O	28	NMOD	O
O	O	O	501	506	based	based	I-NP	JJ	O	24	AMOD	O
O	O	O	507	523	semiquantitative	semiquantitative	I-NP	JJ	O	28	NMOD	O
O	O	O	524	533	detection	detection	I-NP	NN	O	28	NMOD	O
O	O	O	534	540	system	system	I-NP	NN	O	19	OBJ	O
O	O	O	541	546	which	which	B-NP	WDT	O	28	NMOD	O
O	O	O	547	554	enabled	enable	B-VP	VBD	O	29	SBAR	O
O	O	O	555	557	us	us	B-NP	PRP	O	33	SUB	O
O	O	O	558	560	to	to	B-VP	TO	O	33	VMOD	O
O	O	O	561	570	determine	determine	I-VP	VB	O	30	VMOD	O
T6	B-Entity	B-Entity	571	573	NF	NF	B-NP	NN	B-protein	37	NMOD	B-protein
T6	I-Entity	I-Entity	573	574	-	-	O	HYPH	I-protein	37	NMOD	I-protein
T6	I-Entity	I-Entity	574	580	kappaB	kappaB	B-NP	NN	I-protein	37	NMOD	I-protein
O	O	O	581	591	activation	activation	I-NP	NN	O	33	OBJ	O
O	O	O	592	594	in	in	B-PP	IN	O	37	NMOD	O
O	O	O	595	597	ex	ex	B-ADVP	FW	O	40	AMOD	O
O	O	O	598	602	vivo	vivo	I-ADVP	FW	O	45	NMOD	O
O	O	O	603	611	isolated	isolate	B-NP	VBN	B-cell_type	45	NMOD	B-cell_type
O	O	O	612	622	peripheral	peripheral	I-NP	JJ	I-cell_type	45	NMOD	I-cell_type
O	O	O	623	628	blood	blood	I-NP	NN	I-cell_type	45	NMOD	I-cell_type
O	O	O	629	640	mononuclear	mononuclear	I-NP	JJ	I-cell_type	45	NMOD	I-cell_type
O	O	O	641	646	cells	cell	I-NP	NNS	I-cell_type	38	PMOD	I-cell_type
O	O	O	646	647	.	.	O	.	O	19	P	O

O	O	O	648	650	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	651	659	examined	examine	B-VP	VBD	O	0	ROOT	O
O	O	O	660	662	33	33	B-NP	CD	O	4	NMOD	O
O	O	O	663	671	patients	patient	I-NP	NNS	O	2	OBJ	O
O	O	O	672	676	with	with	B-PP	IN	O	4	NMOD	O
O	O	O	677	685	diabetes	diabetes	B-NP	NN	O	7	NMOD	O
O	O	O	686	694	mellitus	mellitus	I-NP	NN	O	5	PMOD	O
O	O	O	695	696	(	(	O	(	O	14	DEP	O
O	O	O	696	700	Type	Type	B-NP	NN	O	12	NMOD	O
O	O	O	701	702	I	I	I-NP	CD	O	9	NMOD	O
O	O	O	703	706	and	and	O	CC	O	12	NMOD	O
O	O	O	707	711	Type	Type	B-NP	NN	O	14	DEP	O
O	O	O	712	714	II	II	I-NP	CD	O	12	NMOD	O
O	O	O	714	715	)	)	O	)	O	7	NMOD	O
O	O	O	715	716	.	.	O	.	O	2	P	O

O	O	O	717	725	Patients	Patient	B-NP	NNS	O	5	SUB	O
O	O	O	726	730	with	with	B-PP	IN	O	1	NMOD	O
O	O	O	731	739	diabetic	diabetic	B-NP	JJ	O	4	NMOD	O
O	O	O	740	751	nephropathy	nephropathy	I-NP	NN	O	2	PMOD	O
O	O	O	752	758	showed	show	B-VP	VBD	O	0	ROOT	O
O	O	O	759	765	higher	high	B-NP	JJR	O	11	NMOD	O
T7	B-Entity	B-Entity	766	768	NF	NF	I-NP	NN	B-protein	9	NMOD	B-protein
T7	I-Entity	I-Entity	768	769	-	-	I-NP	HYPH	I-protein	9	NMOD	I-protein
T7	I-Entity	I-Entity	769	775	kappaB	kappaB	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	O	776	783	binding	binding	I-NP	NN	O	11	NMOD	O
O	O	O	784	792	activity	activity	I-NP	NN	O	20	NMOD	O
O	O	O	793	795	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	796	811	Electrophoretic	Electrophoretic	B-NP	JJ	O	16	NMOD	O
O	O	O	812	820	Mobility	Mobility	I-NP	NN	O	16	NMOD	O
O	O	O	821	826	Shift	Shift	I-NP	NN	O	16	NMOD	O
O	O	O	827	833	Assays	Assay	I-NP	NNS	O	12	PMOD	O
O	O	O	834	837	and	and	O	CC	O	20	NMOD	O
O	O	O	838	846	stronger	strong	B-NP	JJR	O	20	NMOD	O
O	O	O	847	865	immunohistological	immunohistological	I-NP	JJ	O	20	NMOD	O
O	O	O	866	874	staining	staining	I-NP	NN	O	5	OBJ	O
O	O	O	875	878	for	for	B-PP	IN	O	20	NMOD	O
O	O	O	879	888	activated	activate	B-NP	VBN	O	25	NMOD	O
T1	B-Protein	B-Protein	889	891	NF	NF	I-NP	NN	B-protein	25	NMOD	B-protein
T1	I-Protein	I-Protein	891	892	-	-	O	HYPH	I-protein	25	NMOD	I-protein
T1	I-Protein	I-Protein	892	901	kappaBp65	kappaBp65	B-NP	NN	I-protein	21	PMOD	I-protein
O	O	O	902	906	than	than	B-PP	IN	O	20	NMOD	O
O	O	O	907	915	patients	patient	B-NP	NNS	O	26	PMOD	O
O	O	O	916	923	without	without	B-PP	IN	O	27	NMOD	O
O	O	O	924	929	renal	renal	B-NP	JJ	O	30	NMOD	O
O	O	O	930	943	complications	complication	I-NP	NNS	O	28	PMOD	O
O	O	O	943	944	.	.	O	.	O	5	P	O

T8	B-Entity	B-Entity	945	947	NF	NF	B-NP	NN	B-protein	3	NMOD	B-protein
T8	I-Entity	I-Entity	947	948	-	-	I-NP	HYPH	I-protein	3	NMOD	I-protein
T8	I-Entity	I-Entity	948	954	kappaB	kappaB	I-NP	NN	I-protein	5	NMOD	I-protein
O	O	O	955	962	binding	binding	I-NP	NN	O	5	NMOD	O
O	O	O	963	971	activity	activity	I-NP	NN	O	6	SUB	O
O	O	O	972	982	correlated	correlate	B-VP	VBD	O	0	ROOT	O
O	O	O	983	987	with	with	B-PP	IN	O	6	VMOD	O
O	O	O	988	991	the	the	B-NP	DT	O	9	NMOD	O
O	O	O	992	998	degree	degree	I-NP	NN	O	7	PMOD	O
O	O	O	999	1001	of	of	B-PP	IN	O	9	NMOD	O
O	O	O	1002	1013	albuminuria	albuminuria	B-NP	NN	O	10	PMOD	O
O	O	O	1014	1015	(	(	O	(	O	18	DEP	O
O	O	O	1015	1016	r	r	B-NP	NN	O	17	SUB	O
O	O	O	1017	1018	=	=	B-VP	SYM	O	17	VMOD	O
O	O	O	1019	1020	0	0	B-NP	CD	O	17	NMOD	O
O	O	O	1020	1021	.	.	I-NP	SYM	O	17	NMOD	O
O	O	O	1021	1024	316	316	I-NP	CD	O	18	DEP	O
O	O	O	1024	1025	)	)	O	)	O	9	NMOD	O
O	O	O	1026	1029	and	and	O	CC	O	7	PMOD	O
O	O	O	1030	1034	with	with	B-PP	IN	O	7	PMOD	O
T2	B-Protein	B-Protein	1035	1049	thrombomodulin	thrombomodulin	B-NP	NN	B-protein	23	NMOD	B-protein
O	O	O	1050	1056	plasma	plasma	I-NP	NN	O	23	NMOD	O
O	O	O	1057	1071	concentrations	concentration	I-NP	NNS	O	20	PMOD	O
O	O	O	1072	1073	(	(	O	(	O	30	DEP	O
O	O	O	1073	1074	r	r	B-NP	NN	O	29	SUB	O
O	O	O	1075	1076	=	=	B-VP	SYM	O	29	VMOD	O
O	O	O	1077	1078	0	0	B-NP	CD	O	29	AMOD	O
O	O	O	1078	1079	.	.	I-NP	SYM	O	29	AMOD	O
O	O	O	1079	1081	33	33	I-NP	CD	O	30	DEP	O
O	O	O	1081	1082	)	)	O	)	O	23	NMOD	O
O	O	O	1082	1083	,	,	O	,	O	6	P	O
O	O	O	1084	1094	indicative	indicative	B-ADJP	JJ	O	6	VMOD	O
O	O	O	1095	1098	for	for	B-PP	IN	O	32	AMOD	O
O	O	O	1099	1110	albuminuria	albuminuria	B-NP	NN	O	37	NMOD	O
O	O	O	1111	1121	associated	associated	I-NP	JJ	O	34	AMOD	O
O	O	O	1122	1133	endothelial	endothelial	I-NP	JJ	O	37	NMOD	O
O	O	O	1134	1145	dysfunction	dysfunction	I-NP	NN	O	33	PMOD	O
O	O	O	1145	1146	.	.	O	.	O	6	P	O

O	O	O	1147	1149	In	In	B-PP	IN	O	24	VMOD	O
O	O	O	1150	1151	a	a	B-NP	DT	O	6	NMOD	O
O	O	O	1152	1153	3	3	I-NP	CD	O	4	AMOD	O
O	O	O	1154	1157	day	day	I-NP	NN	O	6	NMOD	O
O	O	O	1158	1170	intervention	intervention	I-NP	NN	O	6	NMOD	O
O	O	O	1171	1176	study	study	I-NP	NN	O	1	PMOD	O
O	O	O	1177	1179	in	in	B-PP	IN	O	6	NMOD	O
O	O	O	1180	1185	which	which	B-NP	WDT	O	7	PMOD	O
O	O	O	1186	1189	600	600	B-NP	CD	O	10	NMOD	O
O	O	O	1190	1192	mg	mg	I-NP	NN	O	7	PMOD	O
O	O	O	1193	1195	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	1196	1199	the	the	B-NP	DT	O	15	NMOD	O
O	O	O	1200	1211	antioxidant	antioxidant	I-NP	JJ	O	15	NMOD	O
O	O	O	1212	1220	thioctic	thioctic	I-NP	JJ	O	15	NMOD	O
O	O	O	1221	1225	acid	acid	I-NP	NN	O	11	PMOD	O
O	O	O	1226	1227	(	(	O	(	O	21	DEP	O
O	O	O	1227	1232	alpha	alpha	B-NP	SYM	O	20	NMOD	O
O	O	O	1232	1233	-	-	O	HYPH	O	20	NMOD	O
O	O	O	1233	1239	lipoic	lipoic	B-NP	JJ	O	20	NMOD	O
O	O	O	1240	1244	acid	acid	I-NP	NN	O	21	DEP	O
O	O	O	1244	1245	)	)	O	)	O	15	NMOD	O
O	O	O	1246	1249	per	per	B-NP	IN	O	10	NMOD	O
O	O	O	1250	1253	day	day	I-NP	NN	O	22	PMOD	O
O	O	O	1254	1258	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1259	1264	given	give	I-VP	VBN	O	24	VC	O
O	O	O	1265	1267	to	to	B-PP	TO	O	25	VMOD	O
O	O	O	1268	1272	nine	nine	B-NP	CD	O	28	NMOD	O
O	O	O	1273	1281	patients	patient	I-NP	NNS	O	26	PMOD	O
O	O	O	1282	1286	with	with	B-PP	IN	O	28	NMOD	O
O	O	O	1287	1295	diabetic	diabetic	B-NP	JJ	O	31	NMOD	O
O	O	O	1296	1307	nephropathy	nephropathy	I-NP	NN	O	29	PMOD	O
O	O	O	1308	1317	oxidative	oxidative	I-NP	JJ	O	33	NMOD	O
O	O	O	1318	1324	stress	stress	I-NP	NN	O	37	SUB	O
O	O	O	1325	1327	in	in	B-PP	IN	O	33	NMOD	O
O	O	O	1328	1334	plasma	plasma	B-NP	NN	O	36	NMOD	O
O	O	O	1335	1342	samples	sample	I-NP	NNS	O	34	PMOD	O
O	O	O	1343	1346	was	be	B-VP	VBD	O	25	VMOD	O
O	O	O	1347	1356	decreased	decrease	I-VP	VBN	O	37	VC	O
O	O	O	1357	1359	by	by	B-PP	IN	O	38	VMOD	O
O	O	O	1360	1362	48	48	B-NP	CD	O	41	NMOD	O
O	O	O	1362	1363	%	%	I-NP	NN	O	45	NMOD	O
O	O	O	1364	1367	and	and	I-NP	CC	O	45	NMOD	O
T9	B-Entity	B-Entity	1368	1370	NF	NF	I-NP	NN	B-protein	45	NMOD	B-protein
T9	I-Entity	I-Entity	1370	1371	-	-	I-NP	HYPH	I-protein	45	NMOD	I-protein
T9	I-Entity	I-Entity	1371	1377	kappaB	kappaB	I-NP	NN	I-protein	47	NMOD	I-protein
O	O	O	1378	1385	binding	binding	I-NP	NN	O	47	NMOD	O
O	O	O	1386	1394	activity	activity	I-NP	NN	O	39	PMOD	O
O	O	O	1395	1397	in	in	B-PP	IN	O	38	VMOD	O
O	O	O	1398	1400	ex	ex	B-ADVP	FW	O	50	AMOD	O
O	O	O	1401	1405	vivo	vivo	I-ADVP	FW	O	55	NMOD	O
O	O	O	1406	1414	isolated	isolate	B-NP	VBN	B-cell_type	55	NMOD	B-cell_type
O	O	O	1415	1425	peripheral	peripheral	I-NP	JJ	I-cell_type	55	NMOD	I-cell_type
O	O	O	1426	1431	blood	blood	I-NP	NN	I-cell_type	55	NMOD	I-cell_type
O	O	O	1432	1443	mononuclear	mononuclear	I-NP	JJ	I-cell_type	55	NMOD	I-cell_type
O	O	O	1444	1449	cells	cell	I-NP	NNS	I-cell_type	48	PMOD	I-cell_type
O	O	O	1450	1452	by	by	B-PP	IN	O	38	VMOD	O
O	O	O	1453	1455	38	38	B-NP	CD	O	58	NMOD	O
O	O	O	1455	1456	%	%	I-NP	NN	O	56	PMOD	O
O	O	O	1456	1457	.	.	O	.	O	24	P	O

O	O	O	1458	1460	In	In	B-PP	IN	O	25	VMOD	O
O	O	O	1461	1471	conclusion	conclusion	B-NP	NN	O	1	PMOD	O
O	O	O	1471	1472	,	,	O	,	O	25	P	O
O	O	O	1473	1483	activation	activation	B-NP	NN	O	25	SUB	O
O	O	O	1484	1486	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	1487	1490	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	1491	1504	transcription	transcription	I-NP	NN	B-protein	8	NMOD	B-protein
O	O	O	1505	1511	factor	factor	I-NP	NN	I-protein	11	NMOD	I-protein
T10	B-Entity	B-Entity	1512	1514	NF	NF	I-NP	NN	B-protein	11	NMOD	B-protein
T10	I-Entity	I-Entity	1514	1515	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T10	I-Entity	I-Entity	1515	1521	kappaB	kappaB	I-NP	NN	I-protein	5	PMOD	I-protein
O	O	O	1522	1524	in	in	B-PP	IN	O	4	NMOD	O
O	O	O	1525	1527	ex	ex	B-ADVP	FW	O	14	AMOD	O
O	O	O	1528	1532	vivo	vivo	I-ADVP	FW	O	19	NMOD	O
O	O	O	1533	1541	isolated	isolate	B-NP	VBN	B-cell_type	19	NMOD	B-cell_type
O	O	O	1542	1552	peripheral	peripheral	I-NP	JJ	I-cell_type	19	NMOD	I-cell_type
O	O	O	1553	1558	blood	blood	I-NP	NN	I-cell_type	19	NMOD	I-cell_type
O	O	O	1559	1570	mononuclear	mononuclear	I-NP	JJ	I-cell_type	19	NMOD	I-cell_type
O	O	O	1571	1576	cells	cell	I-NP	NNS	I-cell_type	12	PMOD	I-cell_type
O	O	O	1577	1579	of	of	B-PP	IN	O	19	NMOD	O
O	O	O	1580	1588	patients	patient	B-NP	NNS	O	20	PMOD	O
O	O	O	1589	1593	with	with	B-PP	IN	O	21	NMOD	O
O	O	O	1594	1602	diabetes	diabetes	B-NP	NN	O	24	NMOD	O
O	O	O	1603	1611	mellitus	mellitus	I-NP	NN	O	22	PMOD	O
O	O	O	1612	1622	correlates	correlate	B-VP	VBZ	O	0	ROOT	O
O	O	O	1623	1627	with	with	B-PP	IN	O	25	VMOD	O
O	O	O	1628	1631	the	the	B-NP	DT	O	28	NMOD	O
O	O	O	1632	1638	degree	degree	I-NP	NN	O	26	PMOD	O
O	O	O	1639	1641	of	of	B-PP	IN	O	28	NMOD	O
O	O	O	1642	1650	diabetic	diabetic	B-NP	JJ	O	31	NMOD	O
O	O	O	1651	1662	nephropathy	nephropathy	I-NP	NN	O	29	PMOD	O
O	O	O	1662	1663	.	.	O	.	O	25	P	O

T11	B-Entity	B-Entity	1664	1666	NF	NF	B-NP	NN	B-protein	3	NMOD	B-protein
T11	I-Entity	I-Entity	1666	1667	-	-	I-NP	HYPH	I-protein	3	NMOD	I-protein
T11	I-Entity	I-Entity	1667	1673	kappaB	kappaB	I-NP	NN	I-protein	4	NMOD	I-protein
O	O	O	1674	1684	activation	activation	I-NP	NN	O	5	SUB	O
O	O	O	1685	1687	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1688	1690	at	at	B-ADVP	IN	O	8	PMOD	O
O	O	O	1691	1696	least	least	I-ADVP	JJS	O	6	AMOD	O
O	O	O	1697	1699	in	in	B-PP	IN	O	5	VMOD	O
O	O	O	1700	1704	part	part	B-NP	NN	O	8	PMOD	O
O	O	O	1705	1714	dependent	dependent	B-ADJP	JJ	O	5	PRD	O
O	O	O	1715	1717	on	on	B-PP	IN	O	10	AMOD	O
O	O	O	1718	1727	oxidative	oxidative	B-NP	JJ	O	13	NMOD	O
O	O	O	1728	1734	stress	stress	I-NP	NN	O	11	PMOD	O
O	O	O	1735	1740	since	since	B-PP	IN	O	5	VMOD	O
O	O	O	1741	1749	thioctic	thioctic	B-NP	JJ	O	16	NMOD	O
O	O	O	1750	1754	acid	acid	I-NP	NN	O	23	SUB	O
O	O	O	1755	1756	(	(	O	(	O	22	DEP	O
O	O	O	1756	1761	alpha	alpha	B-NP	SYM	O	21	NMOD	O
O	O	O	1761	1762	-	-	O	HYPH	O	21	NMOD	O
O	O	O	1762	1768	lipoic	lipoic	B-NP	JJ	O	21	NMOD	O
O	O	O	1769	1773	acid	acid	I-NP	NN	O	22	DEP	O
O	O	O	1773	1774	)	)	O	)	O	16	NMOD	O
O	O	O	1775	1782	reduced	reduce	B-VP	VBD	O	14	SBAR	O
T12	B-Entity	B-Entity	1783	1785	NF	NF	B-NP	NN	B-protein	26	NMOD	B-protein
T12	I-Entity	I-Entity	1785	1786	-	-	B-NP	HYPH	I-protein	26	NMOD	I-protein
T12	I-Entity	I-Entity	1786	1792	kappaB	kappaB	I-NP	NN	I-protein	28	NMOD	I-protein
O	O	O	1793	1800	binding	binding	I-NP	NN	O	28	NMOD	O
O	O	O	1801	1809	activity	activity	I-NP	NN	O	23	OBJ	O
O	O	O	1809	1810	.	.	O	.	O	5	P	O
